Chester County News and Community Website
HATFIELD, PA — AllerGenis, a predictive data analytics company specializing in the detection and management of life-threatening immune response disorders including food allergy, announced the publication of a peer-reviewed study entitled, “Accurate …
Read More HATFIELD, PA — AllerGenis, a predictive data analytics company specializing in the detection and management of life-threatening immune response disorders initially focused on food allergy, announced that the company’s chief scientific …
Read More
WASHINGTON, D.C. — The following quote is attributed to Tim Stenzel, M.D., Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices …
Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or …
Read More
EXTON, PA — Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced that it advanced its …
Read More
WASHINGTON, D.C. — The U.S. Department of Health and Human Services (HHS) is investing $150 million to increase access to COVID-19 monoclonal antibody therapeutic treatments for patients in vulnerable communities …
Read More WASHINGTON, D.C. — The Centers for Disease Control and Prevention (CDC) issued its first set of recommendations on activities that people who are fully vaccinated against COVID-19 can safely resume.
Read MoreWASHINGTON, D.C. — The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by Adaptive Biotechnologies. The T-Detect COVID Test is a …
Read More
EXTON, PA — Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced that its discovery engine …
Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced the release of findings from …
Read More